Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
2
×
boston
boston blog main
boston top stories
clinical trials
2
×
drugs
fda
2
×
life sciences
national blog main
patisiran
rna interference
acute hepatic porphyrias
akcea therapeutics
akin akinc
aminolevulinic acid
barry greene
biotech
boston university
dan ollendorf
givosiran
hereditary transthyretin amyloidosis
inotersen
john berk
mary o'donnell
national top stories
new york blog main
new york top stories
onpattro
paul matteis
regeneron pharmaceuticals
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
stifel financial
tafamidis
the amyloidosis foundation
the institute for clinical and economic review
vyndaqel
What
ago
alnylam
fda
medicine
rna
2
×
approval
approve
awaits
biological
crossed
decades
decision
discovered
drug
fingers
friday
historic
indicated
interference
nod
patients
pharmaceuticals
quick
rnai
second
seek
speedy
time
trick
uses
weeks
won’t
Language
Current search:
rna
×
fda
×
" clinical trials "
×
" alnylam pharmaceuticals "
×
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
6 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision